TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
29.19
-0.08 (-0.27%)
Mar 9, 2026, 4:00 PM EDT - Market closed
TG Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 616.29 | 329 | 233.66 | 2.79 | 6.69 | Upgrade
|
| Revenue Growth (YoY) | 87.32% | 40.80% | 8290.02% | -58.36% | 4300.66% | Upgrade
|
| Cost of Revenue | 100.71 | 38.49 | 14.13 | 0.27 | 0.79 | Upgrade
|
| Gross Profit | 515.57 | 290.52 | 219.53 | 2.52 | 5.9 | Upgrade
|
| Selling, General & Admin | 232.03 | 154.3 | 122.71 | 95.48 | 128.09 | Upgrade
|
| Research & Development | 160.22 | 94.29 | 76.19 | 125.35 | 222.58 | Upgrade
|
| Operating Expenses | 392.25 | 248.59 | 198.9 | 220.84 | 350.67 | Upgrade
|
| Operating Income | 123.32 | 41.93 | 20.63 | -218.32 | -344.77 | Upgrade
|
| Interest Expense | -26.73 | -24.03 | -12.62 | -10.19 | -5.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.79 | 7.69 | 5.04 | 4.7 | 2.31 | Upgrade
|
| Pretax Income | 107.39 | 25.59 | 13.06 | -223.81 | -348.1 | Upgrade
|
| Income Tax Expense | -339.79 | 2.21 | 0.39 | - | - | Upgrade
|
| Net Income | 447.18 | 23.38 | 12.67 | -223.81 | -348.1 | Upgrade
|
| Net Income to Common | 447.18 | 23.38 | 12.67 | -223.81 | -348.1 | Upgrade
|
| Net Income Growth | 1812.41% | 84.52% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 144 | 145 | 142 | 135 | 132 | Upgrade
|
| Shares Outstanding (Diluted) | 161 | 160 | 149 | 135 | 132 | Upgrade
|
| Shares Change (YoY) | 0.67% | 7.96% | 9.67% | 2.41% | 14.64% | Upgrade
|
| EPS (Basic) | 3.10 | 0.16 | 0.09 | -1.65 | -2.63 | Upgrade
|
| EPS (Diluted) | 2.77 | 0.15 | 0.09 | -1.65 | -2.63 | Upgrade
|
| EPS Growth | 1746.67% | 68.03% | - | - | - | Upgrade
|
| Free Cash Flow | -24.99 | -40.56 | -31.41 | -176.18 | -296.04 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.25 | -0.21 | -1.30 | -2.24 | Upgrade
|
| Gross Margin | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% | Upgrade
|
| Operating Margin | 20.01% | 12.74% | 8.83% | -7838.99% | -5154.28% | Upgrade
|
| Profit Margin | 72.56% | 7.11% | 5.42% | -8036.34% | -5204.08% | Upgrade
|
| Free Cash Flow Margin | -4.05% | -12.33% | -13.44% | -6326.18% | -4425.70% | Upgrade
|
| EBITDA | 123.38 | 42 | 20.84 | -218.01 | -344.49 | Upgrade
|
| EBITDA Margin | 20.02% | 12.77% | 8.92% | - | - | Upgrade
|
| D&A For EBITDA | 0.06 | 0.07 | 0.21 | 0.3 | 0.28 | Upgrade
|
| EBIT | 123.32 | 41.93 | 20.63 | -218.32 | -344.77 | Upgrade
|
| EBIT Margin | 20.01% | 12.74% | 8.83% | - | - | Upgrade
|
| Effective Tax Rate | - | 8.64% | 2.99% | - | - | Upgrade
|
| Revenue as Reported | 616.29 | 329 | 233.66 | 2.79 | 6.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.